



# **Therapeutic Goods (Poisons Standard) (COVID-19 Treatment—GlaxoSmithKline) (Sotrovimab) Labelling Exemption 2021**

---

I, John Skerritt, as the appropriate authority, grant the following labelling exemption.

Dated 12 August 2021

Adjunct Professor John Skerritt  
Deputy Secretary  
Health Products Regulation Group  
Department of Health

---

---

# Contents

1 Name.....	1
2 Commencement .....	1
3 Authority .....	1
4 Definitions .....	1
5 Exemption.....	2

---

## 1 Name

This instrument is the *Therapeutic Goods (Poisons Standard) (COVID-19 Treatment—GlaxoSmithKline) (Sotrovimab) Labelling Exemption 2021*.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day after this instrument is made.	13 August 2021

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.

## 4 Definitions

Note 1: A number of expressions used in this labelling exemption are defined in section 3 of the Act, including the following:

- (a) current Poisons Standard;
- (b) Register.

Note 2: A number of expressions used in this labelling exemption are defined in section 1 of Part 1 of the current Poisons Standard, including the following:

- (a) appropriate authority.

In this instrument:

*Act* means the *Therapeutic Goods Act 1989*.

*specified product* means the medicine that:

- (a) contains the active ingredient sotrovimab; and
- (b) has an indication accepted in relation to its inclusion in the Register that relates to the treatment of coronavirus disease 2019 (COVID-19); and
- (c) is manufactured, imported or supplied by GlaxoSmithKline Australia Pty Ltd.

---

## 5 Exemption

The specified product is exempt from the labelling requirements in:

- (a) section 1.3(1)(a) of Part 2 of the current Poisons Standard; and
- (b) section 1.3(1)(c) of Part 2 of the current Poisons Standard; and
- (c) section 1.3(1)(k) of Part 2 of the current Poisons Standard; and
- (d) section 1.4(1)(a) of Part 2 of the current Poisons Standard.

Note 1: Under section 1.1(1) of Part 2 of the current Poisons Standard, a scheduled substance or preparation must not be supplied unless labelled in accordance with section 1 of Part 2 of the current Poisons Standard.

Note 2: Section 5 of this instrument exempts the specified product from the following labelling requirements in section 1 of Part 2 of the current Poisons Standard:

- (a) labelling of the primary pack and immediate container with signal words, as required by section 1.3(1)(a);
- (b) labelling of the primary pack and immediate container with the cautionary statement 'KEEP OUT OF REACH OF CHILDREN', as required by section 1.3(1)(c);
- (c) labelling of the primary pack and immediate container with the approved name and a statement of the quantity, proportion or strength, as required by sections 1.3(1)(k) and 1.4(1)(a).